ACOR News and Press, Acorda Therapeutics Inc. From 03/27/23

April 4, 2023 at 1pm ET, 10am PT Participants Invited to Submit Questions to the CEO Acorda Therapeutics, Inc. (Nasdaq: ACOR) will hold a virtual, video Q&A with its CEO, Ron Cohen, M.D., on Tuesday, April 4 at 1:00pm ET, 10:00am PT. Dr. Cohen will present an overview of...

2023-03-24 22:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-03-10 18:09:06 ET Acorda Therapeutics, Inc. (ACOR) Q4 2022 Earnings Conference Call March 9, 2023 8:30 AM ET Company Participants Tierney Saccavino - Investor Relations Ron Cohen - President and Chief Executive Officer Michael Gesser - Chief Financial Office...

2023-03-09 12:52:22 ET Acorda Therapeutics ( NASDAQ: ACOR ) stock fell ~4% on Thursday following Q4 results. Q4 Net income was $19.14M, compared to net loss of -$20.57M in Q4 2021. Total revenues declined -14.8% to -$31.47M. Net product revenues fell -15.4% Y/Y to $2...

2023-03-09 08:45:20 ET Silvergate Capital SI -36% on plans to wind down operations, liquidate Silvergate Bank . SVB Financial SIVB -28% on $1.25B stock offering, $500M depositary share offering . Arhaus ARHS -11% on Q4 earnings release . Altamira Th...

2023-03-09 07:01:47 ET Acorda Therapeutics press release ( NASDAQ: ACOR ): Q4 GAAP EPS of $0.57. Revenue of $31.47M (-12.8% Y/Y). For the full year 2023, the Company is targeting INBRIJA U.S. net revenue to be $38 - $42 million. The Company is targeting a...

INBRIJA ® (levodopa inhalation powder) 2022 U.S. net revenue of $28.0MM and ex-U.S. net revenue of $2.9MM; Q4 2022 U.S. net revenue of $9.0MM AMPYRA ® (dalfampridine) Extended Release Tablets, 10 mg 2022 net revenue of $72.9MM and FAMPYRA royalty revenue of $11.7MM; Q4 2022 ...

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Esteve Pharmaceuticals, S.A. has launched INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Spain. INBRIJA is indicated in the EU for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with ...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will host a webcast/conference call in conjunction with its fourth quarter and year end 2022 update and financial results on Thursday, March 9 at 8:30 a.m. ET. To participate in the Webcast, please use the following registration link: https://e...

2023-03-05 14:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...